Cargando…

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes

Dapagliflozin belongs in the family of sodium-glucose cotransporter 2 (SGLT2) inhibitors and acts by reducing glucose reabsorption in the proximal tubule. The aim of this review is to present the differential pharmacology and clinical utility of dapagliflozin. Dapagliflozin is orally administered, h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papakitsou, Ioanna, Vougiouklakis, George, Elisaf, Moses S, Filippatos, Theodosios D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756826/ https://www.ncbi.nlm.nih.gov/pubmed/31572020 http://dx.doi.org/10.2147/CPAA.S172353

Ejemplares similares

Effects of Angiopoietin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes
por: Christopoulou, Eliza, et al.
Publicado: (2019)

Thiazide–associated hyponatremia in the elderly: what the clinician needs to know
por: Liamis, George, et al.
Publicado: (2016)

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
por: Filippatos, Theodosios D., et al.
Publicado: (2017)

Hyponatremia in the elderly: challenges and solutions
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

Non-hemorrhage-related adverse effects of rivaroxaban
por: Christopoulou, Eliza C., et al.
Publicado: (2017)

PCSK9 and carbohydrate metabolism: A double-edged sword
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

Effects of increased body weight and short-term weight loss on serum PCSK9 levels – a prospective pilot study
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study
por: Filippatos, Theodosios D., et al.
Publicado: (2013)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
por: Munir, Kashif M, et al.
Publicado: (2016)

LDL cholesterol estimation in patients with the metabolic syndrome
por: Gazi, Irene, et al.
Publicado: (2006)

Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates
por: Ioannou, Petros, et al.
Publicado: (2023)

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Correction to: Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes
por: Iijima, Yasuhiro, et al.
Publicado: (2023)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
por: Saeed, Mujahid A, et al.
Publicado: (2014)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes
por: Bletsa, Evdoxia, et al.
Publicado: (2021)

Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
por: Salvo, Marissa C, et al.
Publicado: (2014)

Abstract 52: Clinical efficacy of dapagliflozin in patients with newly diagnosed type 2 diabetes
por: Patil, Surekha Mahesh
Publicado: (2022)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Correction to: Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Dapagliflozin: an effective adjunctive treatment in type 1 diabetes
por: Yadegarfar, Ghasem, et al.
Publicado: (2021)

A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
por: Filippatos, Theodosios D.
Publicado: (2012)

Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
por: Imamura, Akira, et al.
Publicado: (2013)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos, Ioannis, et al.
Publicado: (2019)

Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea
por: Park, Sang Hyun, et al.
Publicado: (2019)

Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin
por: Zhao, Yan-Xue, et al.
Publicado: (2022)

Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer’s Perspective
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2021)

Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2021)

The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy
por: Huang, Ying, et al.
Publicado: (2022)

Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
por: Chao, Edward C
Publicado: (2012)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker, Catherine M, et al.
Publicado: (2016)

Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model
por: Yang, Mei, et al.
Publicado: (2020)

Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
por: Wolf, Vaneza Lira W., et al.
Publicado: (2021)

Frequency of Urinary Tract Infections in Type 2 Diabetic Patients Taking Dapagliflozin
por: Khan, Sarfaraz, et al.
Publicado: (2022)

Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes
por: Liu, Jia, et al.
Publicado: (2023)

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
por: Heerspink, H J Lambers, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2hsjvpsp2akgak05e6pc2dt9bs